Universal nanosponge for treating respiratory viral infection
US12083162B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 22, 2021 |
| Grant date | Sep 10, 2024 |
| Priority date | — |
| Expiry date | May 14, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/5176
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A nanoparticle comprising an outer surface comprising a plasma membrane derived from a cell that can be infected with a respiratory virus, including a human lung epithelial cell expressing ACE-2 receptor. Methods of manufacture and use for preventing or treating viral infections, such as coronavirus infection in a subject in need are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.